A kinurénsav termelődés anatómiai és funkcionális vizsgálata egér agyszövetben by HASH(0x7fe99051e9b0)
1 
 
 
Anatomical and functional characterization of 
kynurenic acid production in the mouse brain 
Summary of Ph.D. Thesis 
Judit Herédi 
 
 
 
Supervisors  
 Dr. Levente Gellért   Dr. Zsolt Kis 
  assistant professor                     assistant professor  
 
Ph.D. School in Biology 
University of Szeged 
Department of Physiology, Anatomy and Neuroscience  
Szeged, 2018 
 
 
2 
 
 
1. Introduction 
Kynurenine pathway (KP) is the main metabolic route of tryptophan (TRP) 
degradation in the mammalian brain which leading to the production of several 
neuroactive metabolites. One of the KP end products, kynurenic acid (KYNA) is 
widely studied as a neuromodulator and neuroprotective agent in the central 
nervous system (CNS). 
KYNA has a broad-spectrum receptor modulatory effect both on ionotropic and 
metabotropic receptors. The main targets of KYNA in the brain are the N-methyl-
D-aspartate (NMDA) and the α7 nicotinic acetylcholine (α7nACh) receptors, 
through which KYNA can modulate the level of glutamate, acetylcholine, GABA 
and also dopamine in the CNS. 
Along with other metabolites, KYNA has been implicated in several brain 
disorders, so manipulation of the KP has high therapeutic potential. Decreased 
KYNA level has been observed in neurodegenerative disorders such as 
Huntington’s and Parkinson’s disease, while in disorders where cognitive functions 
are impaired -e.g. schizophrenia- KYNA is abnormally increased. Therefore both 
up and down regulation of KYNA production could serve as a potential 
therapeutical strategy. 
KYNA is produced from L-kynurenine (L-KYN) by the action of kynurenine 
aminotransferases (KAT). So far, four KAT isoforms (KAT-1-4) have been 
identified from which KAT-2 is considered to be the major biosynthetic enzyme of 
KYNA in the human brain. Therefore studies investigating KYNA production are 
focusing on KAT-2 in rodents.The prevailing view about KAT-2 presence and 
KYNA production based on immunohistochemical studies carried out on rats, that 
it is localized in astrocytes and KYNA is released mainly by this cell type in the 
brain. Neuronal expression of the enzyme was only sporadic through the rat brain. 
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The pharmacological and genetic manipulation of KYNA production has been 
widely studied in rodents. Although the effect of genetic manipulations of the 
KYN pathway has been described in mice, the kat-2 knock-out model suffers from 
the general limitations of the null-mutant models in which peripheral KYNA 
function is also influenced. To investigate tissue- and cell-type-speciﬁc function 
of KAT-2, one needs spatio-temporally selective kynurenergic manipulation, 
which is possible only if the expression proﬁle of KAT-2 is well described in 
the wild-type animal. However, we have little information regarding the 
expression and function of KAT-2 in mice. 
While L-KYN readily pass through the blood brain barrier (BBB) kynurenic acid 
has a very limited ability to penetrate the BBB. So the easiest pharmacological tool 
to increase brain KYNA level is the administration of L-KYN, which resulted in a 
significant elevation of KYNA both in vitro and in vivo. The advantage of using 
acute brain slice preparations is that kynurenergic manipulation can be studied in a 
tissue specific manner without affecting the peripheral KYNA function. 
Previously KYNA production and release to the extracellular compartment 
upon L-KYN exposure was described in acute rat brain slices. However, there 
is no data about the basal and L-KYN induced KYNA production of acute 
mouse brain slice preparations. 
Inhibiting KP enzymes is another promising tool to decrease or increase KYNA 
production with the aim of therapy. Shifting the KP toward KYNA synthesis with 
kynurenine 3-monooxygenase (KMO) inhibition studied in brain disease models 
like Alzheimer’s or Huntington’s disease, while lowering KYNA level with 
selective KAT-2 inhibitors improves cognitive function under conditions 
considered relevant for schizophrenia. No pharmacological experiment has yet 
targeted the mouse KAT-2 function, probably because of its proposed 
irrelevance in the mouse species. 
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Complicating therapeutical KP manipulation that there are prominent differences 
among mammalian species regarding the kynurenine system. For example, the 
KYNA synthesizing enzyme isoforms have a different role in different species. In 
the human and rat brain KAT-2 plays the major role in KYNA production, whereas 
in mice KAT-2 function is questionable. Therefore comparative 
characterization of the kynurenine catabolism in different model species is 
essential before assigning therapeutical kynurenergic manipulation strategies 
in humans. 
 
2. Aims 
During our experiments we investigated the kynurenic acid production in the 
mouse brain. The main aims of the present study were to: 
Aim 1: Clarify the presence of kat-2 mRNA and protein in adult mouse brain 
tissue. 
Aim 2: Develop an in vitro incubation system, where KYNA production can be 
investigated and manipulated in acute mouse brain slices.Test the after-incubation 
state of the brain slices in our system. 
Aim 3: Investigate the basal and L-KYN induced KYNA production in acute 
mouse brain slices.  
Aim 4: Evaluate the effect of KAT-2 inhibition in the mouse brain tissue with a 
selective KAT-2 inhibitor. 
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3. Materials and methods 
8-12 week-old male C57Bl/6 mice were used during our experiments. 
3.1 Anatomical study of the kynurenine system 
3.1.1 Tissue preparation 
Animals were deeply anesthetized with an intraperitoneal injection of urethane (1.6 
g/bwkg) and were perfused transcardially with ice-cold 0.1 M phosphate buffer 
(PB, pH 7.4) following 4 % paraformaldehyde (PFA). The brains were removed 
and post-ﬁxed overnight in 4 % PFA. All solutions were treated with 
diethylpyrocarbonate (DEPC) to avoid RNAse contamination during RNA in situ 
hybridization. 
3.1.2 RNA in situ hybridization 
For detection of kat-2 mRNA, in situ hybridization was performed. Sections were 
extensively washed in DEPC-treated PB containing 0.2 % Tween-20 (PBT, pH 
7.4), digested with proteinase K for and post-ﬁxed with 4 % PFA. After thorough 
washing in PB, slices were prehybridized for 1 h at 65 ºC in hybridization buffer 
and then hybridized overnight at 65 ºC in the same solution containing the DIG-
labelled sense or antisense probe for kat-2 mRNA (~300 ng/ml). Next day, 
stringent washes were performed in descending concentrations of the hybridization 
buffer, then sections were blocked with 1 % NDS and incubated in AP-conjugated 
anti-DIG antibody overnight on 4 ºC. The following day samples were exposed to 
the NBT-BCIP substrate. Enzymatic reaction was stopped with PB (pH 7.4) and 
sections were coverslipped with aqueous mounting medium 
3.1.3 Immunohistochemistry 
Free-ﬂoating sections were washed in PBT and incubated in 1 % NDS. For the 
detection of KAT-2 and identiﬁcation of the cells containing the enzyme, sections 
were exposed to the primary antibodies overnight at 4 ºC. Next day, samples were 
6 
 
incubated in the appropriate secondary antibodies at room temperature. Nuclei 
were labelled with 4',6-diamidino-2-fenilindol (DAPI). 
3.1.4 Transfection and immunocytochemistry 
Cells (HeLa ATCC® CCL2 ™) were plated on poly-lysinated dishes and were 
grown until 80% confluency at 37°C (5% CO2). Cells were then transfected with 2 
µg of the kat-2 cDNA vector with FuGENE® HD Transfection Reagent prepared 
as recommended. After 48 hours incubation (37°C, 5% CO2) cells were washed 
with PBS, and fixed with 4% PFA for 15 minutes. Cells were permeabilized with 
0.1% Triton X-100. Non-specific antibody binding was blocked with 3% bovine 
serum albumin (BSA)-PBS solution for 1 hour. Cells were incubated in 4µg/ml of 
the primary antibody diluted in the blocking solution on 4°C, overnight. After 
thorough washing with PBS cells were incubated in the secondary antibody for 2 
hours at RT. Digital photomicrographs were obtained with fluorescence 
microscope (BZ-X700, Keyence Corp.) 
3.1.5 SDS gel electrophoresis (SDS-PAGE) and Western blot 
The specificity of KAT-2 primary antibody was tested by SDS-PAGE and Western 
blot analysis. Protein samples from mouse brain tissue and HeLa cell culture were 
separated on a 8% gel at 100V for 1 h. Proteins were blotted to a PVDF membrane 
using a transfer buffer. After blotting, the membrane was washed and blocked with 
5% nonfat dried milk. Membranes were probed to the primary antibody at 4˚C 
overnight. Next day the membranes were washed extensively and incubated with 
the HRP-conjugated secondary antibody for 1 h. The immunoreactive bands were 
visualized with a chemiluminescent kit and digital images were captured with Li-
Cor C-DIGIT Blot Scanner. 
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3.2 Functional study of the kynurenine system 
3.2.1 Tissue preparation for the in vitro studies 
350 µm  thick  sections  were  obtained  with  a  vibratome  (Leica VT1200S,  
Germany);  the  two  hemispheres  were  dissected  and  transferred  to  a  holding 
chamber. Slices were allowed to recover for 30 min in aCSF. After recovering, one 
hemisphere of the slices were transferred to the incubation chambers containing a 
low bulk volume of ACSF (appr. 6ml of ACSF/100mg wet weight brain tissue) at 
30 °C to reach optimal temperature for KAT-2 function. 
3.2.2 Groups 
For testing the after-incubation state of the brain slices in our system  we examined 
two groups:(1) brain slice halves  kept  under  standard  conditions  (high  bulk  
volume  ofACSF;  ≈200ml/6half  coronal slice)  (LV  condition  hereafter) and 
(2) brain slices transferred to our incubation chambers containing a low bulk 
volume of ACSF (appr. 6ml of aCSF/100mg wet weight brain tissue) (SV  
condition  hereafter). 
For investigating the L-KYN induced KYNA production we use 10 µM L-KYN, 
while the effect of KAT-2 inhibition was tested with PF-04859989 dissolved in 
ACSF in a final concentration of 5µM. 
3.2.3 HPLC 
KYNA level in the supernatants derived from the tissue and ACSF were measured 
with an Agilent 1100 HPLC system combined with a fluorescence and a UV 
detector. For the determination of KYNA, the excitation and emission wavelengths 
of FLD were set at 344 nm and 398 nm, whereas the UV detector was set at 365 
nm for the determination of 3-NLT (internal standard). Chromatographic 
separations were performed on  a  Kinetex  C18  column  preceded  by  Security  
Guard  pre-column  C18. 
3.2.4 Cresyl violet staining 
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We  performed  cresyl  violet  staining  for  morphological  observations after  
different  incubation  conditions.  Sections were rehydrated with descending grades 
of alcohol and stained with cresyl violet staining solution for 5 min. After staining, 
samples were passed through ascending alcohol solutions and immersed in xylene 
for 5 min. Sections were coverslipped with Entallan®. 
3.2.5 Immunohistochemistry 
Fixed brain slices were cryoprotected with sucrose solution and 30 µm thick 
sections were cut with a freezing microtome (Reichert-Jung 1206). For staining 
protocol see section 3.1.3. 
3.2.6 Electrophysiology 
Baseline synaptic function of the tissue was tested with input-output (I/O) curve 
recordings, while short term plasticity with paired-pulse paradigm on the CA3-
CA1 cell synapses in the hippocampus. After 4 h incubation in the LV or SV 
condition, the slices were transferred to an interface recording chamber and 
superfused with aCSF. Schaffer collaterals were stimulated using a concentric 
bipolar stainless steel electrode (Neuronelektrod Ltd, Hungary). fEPSPs were 
recorded from the stratum radiatum of CA1 region with 1,5–3 mOhm resistance 
glass microelectrodes. Potentials were amplified and filtered with WPI AMP-04 
amplifier and digitalized with Axon Digidata 1320A. Recordings were monitored 
and saved with Axoscope 10.0. 
3.2.7 Lactate dehydrogenase (LDH) assay 
For evaluating tissue viability we performed LDH activity assay on supernatant 
samples collected after 30 min, 4 h and 6 h incubation time. As positive control for 
LDH release we permeabilized the cell membrane with Triton X-100™ (1%). LDH 
activity was measured at 340 nm and 37 ˚C using an LDH activity assay kit on a 
BioLis 24i Premium system (Siemens). LDH activity was expressed as U/l/100 mg 
tissue. 
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3.2.8 Hexokinase (HK) assay 
Glucose content was measured by HK activity assay on supernatant samples 
collected after 30 min, 4h and 6h incubation time. HK activity was measured at 
340 nm and 37 ˚C using a two-step Glu HK activity assay kit on a BioLis 24i 
Premium system (Siemens). 
4. Results 
4.1 Anatomical study of the kynurenine system 
4.1.1 Localization of kat-2 mRNA and KAT-2 protein  
First we examined the kat-2 mRNA and KAT-2 protein localization in the mouse 
brain tissue with RNA in situ hybridization and immunohistochemistry. Similar to 
previous observations achieved in rats, glial presence of KAT-2 was significant 
both at the mRNA and protein level in several brain areas. 
However, neuronal expression of KAT-2 was also pronounced throughout the 
mouse brain. Neurons expressing KAT-2distributed sporadically in the CA1 area 
of the hippocampus, dorsal striatum, and all layers of the medial prefrontal cortex , 
whereas there was a signiﬁcant number of KAT-2+/NeuN+cells in the substantia 
nigra. The vast majority of these neurons were identiﬁed as GABAergic inhibitory 
cells in the examined brain areas. 
We also examined the presence of KAT-2 in adult male Wistar rats. We found 
similar astrocytic and neuronal expression pattern of KAT-2 in the rat brain, which 
indicates that it is phylogenetically conserved in rodents. 
These results support the growing body of evidence about neuronal KYNA 
synthesis and contradicts the previous common view that astrocyte is the only 
relevant KYNA producing cell type. Astrocytes and neurons may have a distinctive 
role in KYNA production in health and disease, which should be investigated in 
the future. 
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4.2. Functional study of the kynurenine system 
4.2.1 The structural and functional integrity of the acute brain slices 
During the functional studies we used a custom made in vitro incubation system, 
where the brain slices were incubated in a small volume of ACSF. Therefore we 
first tested the structural and functional integrity of brain slices in our system after 
4 hour incubation time. We performed anatomical, biochemical and 
electrophysiological experiments. 
First,  we  asked  if  the  glucose  availability  in  the  ACSF  under  SV condition 
exceeds the nutrition demand of the slices. Glucose consumption measurement 
proved that glucose availability gradually decreased during the incubation. Glucose 
concentration was already dropped after 30 min, which was further declined after 
4h incubation. 
Alteration in LDH release to the extracellular space is a sensitive measure of cell 
viability. Under SV condition LDH release was continuously increasing in the 
ACSF during 30 min and 4 h. However, Tx-100 treatment resulted in a ≈14 fold 
increase of LDH in the ACSF after 4h incubation. This indicates that the cell 
membrane integrity is largely preserved in the course of 4h incubation. 
For the histological examination of tissue state we performed NeuN 
immunolabelling and cresyl violet staining. There was no visible tissue damage in 
the vulnerable CA1 subregion of the dorsal hippocampus. CA1 pyramidal cell 
shape and size appeared normal after 4h incubation. However, the structural 
integrity of pyramidal cells in CA3 was not completely preserved. Cytosolic NeuN 
immunopositivity decreased and pyramidal cells deformed in the CA3. 
To examine whether the function of astrocytes and neurons- the main sources of 
KYNA- had changed, we performed c-Fos immunolabelling on LV and SV brain 
sections. c-Fos positivity markedly reduced in neurons of the hippocampal CA1 
subregion and strongly increased in astrocytes in other hippocampal areas (and also 
in the cortex) in our SV condition, indicating functional changes to these cells. 
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We  also  tested  the baseline synaptic function and the  plastic  properties  of  the  
slices  in  the  dorsal hippocampal area with I/O curve recordings and paired pulse 
paradigm. There was no significant difference in the I/O curve and paired-pulse 
ratio between the slices incubated under LV or SV condition, which indicates that 
the functional integrity of the brain tissue was preserved after 4 h SV incubation. 
Although, we detected mild alteration in glial and neuronal function, brain slices 
remained metabolically active and brain tissue integrity were mainly preserved for 
further pharmacological experiments. 
4.2.2 KYNA production in mouse brain slices 
To examine whether mouse brain slices liberate endogenous and de novo produced 
KYNA upon L-KYN administration during 4 h long incubation period we 
performed HPLC measurements from brain tissue homogenate and from 
incubating ACSF. Both basal and L-KYN induced KYNA production could be 
measured in our system. As a result of 10 µM L-KYN administration we found a 
6.3 fold increase in the ACSF  and  a  3.8  fold  increase  in  the  tissue KYNA  
content. Furthermore, ≈97%  of  the  total  KYNA  content  was  released  to  the  
extracellular compartment (ACSF), whereas only ≈3% remained in the tissue under 
both condition. 
Finally, we investigated the effect of the KAT-2 inhibitor on the L-KYN-induced 
KYNA release. Similar to former results, high KYNA content could be measured 
in the L-KYN group.  Addition  of  the  inhibitor  resulted  in  a  significant  
decrease  of  the released KYNA in the ACSF by almost 40%. 
Summarize the functional experiments, brain tissue integrity remained sufficient to 
exclude that the observed KYNA release is a simple consequence of general cell 
degradation in our incubation system. For the first time in the literature we proved 
that the mouse brain tissue intensively produces and liberates KYNA into the 
extracellular milieu. Furthermore, KAT-2 inhibition significantly attenuates 
KYNA production, which indicates an important role of KAT-2 isoform in the 
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mouse brain tissue as well. Further in vivo and in vitro experiments are needed to 
clarify the precise role of KAT-2 and the mechanism of KYNA production and 
release in the mouse brain. 
Summary 
During our experiments we investigated KYNA production in the mouse brain 
tissue. We got the following main results: 
1) We demonstrated for the ﬁrst time that KAT-2 is localized both in astrocytes 
and neurons in the adult mouse brain. Furthermore we identified the GABAergic 
nature of KAT-2 containing neurons.  
 
2) We developed a custom made in vitro incubation system. We tested the 
structural and functional integrity of brain slices in our system after 4 hour 
incubation time. Although, we detected mild alteration in glial and neuronal 
function, brain slices remained metabolically active and brain tissue integrity were 
mainly preserved for further pharmacological experiments. 
3) We proved that mouse brain slices intensively produce and liberate KYNA to 
the extracellular compartment, while only a small proportion retained in the tissue 
both in the basal and L-KYN supplemented state. 
4) Finally, we evaluated the effect of specific KAT-2 inhibition with the 
irreversible inhibitor PF-04859989. The inhibitor reduced extracellular KYNA 
content by almost 40% in the ACSF. 
Taken together we can conclude that our anatomical and functional results 
regarding the KYNA production in the mouse brain are filling a research gap 
in the literature and support future pharmacological and genetic 
kynurenergic manipulation studies in mice. 
 
 
